Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Benzimidazoles Stories

2011-05-19 07:00:00

RIDGEFIELD, Conn., May 19, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has received preferred Tier 2 formulary status with all AARP Medicare Part D plans through its pharmacy benefits manager, Prescription Solutions®. The AARP plans, which include AARP Medicare Rx and AARP MedicareComplete from Secure Horizons, provide prescription drug access to nearly 6.8...

2011-05-18 00:17:45

In an evaluation of contemporary antireflux therapies for chronic gastroesophageal reflux disease (GERD), most patients who received treatment with either the proton pump inhibitor esomeprazole or laparoscopic antireflux surgery achieved and remained in disease remission for 5 years, according to a study in the May 18 issue of JAMA. "GERD is a highly prevalent disorder caused by the reflux of gastric contents into the esophagus. It is a chronic, relapsing disease that negatively affects...

2011-04-19 09:45:00

HOUSTON, April 19, 2011 /PRNewswire/ -- An Ohio woman suffered bone deterioration and broken bones because of hidden risks with pharmaceutical giant AstraZeneca's acid reflux drug Nexium, The Gibson Law Firm alleges in a lawsuit filed today in Texas federal court. Filed in the U.S. District Court in Houston, the lawsuit alleges 58-year-old Ginny Begin, of Toledo, Ohio, suffered serious bone deterioration after taking Nexium on a daily basis between 2003 and early 2011. In March, the FDA...

2011-04-05 09:30:00

NEW ORLEANS, April 5, 2011 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. (Takeda) announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than...

2011-02-14 09:00:00

CHAPEL HILL, N.C., Feb. 14, 2011 /PRNewswire/ -- Thought Leader Select, a Research Triangle, NC firm focused on collaborations between the biopharmaceutical industry and the medical community, announces the launch of a new media partnership with biopharmaceutical industry blog Marketing4Health. The research and consulting firm (Thought Leader Select) has signed on to become the blog's exclusive sponsor, beginning February 14, 2011. With a growing international following and strong...

2011-01-19 13:38:00

RADNOR, Pa., Jan. 19, 2011 /PRNewswire/ -- HTH Worldwide, a global health and safety services company, today announced the expansion of its mobile and online brand name medication translation guide for world travelers. Prescription and over-the-counter drug names often vary by country -- for example Prilosec is called Lomac or Prilosid in India -- so those traveling, living or studying abroad need to be sure they are getting the precise equivalent of medications they were prescribed at...

2011-01-05 07:00:00

RIDGEFIELD, Conn., Jan. 5, 2011 /PRNewswire/ -- Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to normal sinus rhythm, were published online on Jan. 3 in Circulation.(1) Stroke and systemic embolism and major bleeding episodes within 30 days of the cardioversion were the major outcome measures. The analysis reported that rates of...

2010-11-25 21:43:30

Despite the reassurances of Pasternak and Hviid in their study, "Use of Proton-Pump Inhibitors (PPI) in Early Pregnancy and the Risk of Birth Defects," featured in the Nov. 24 issue of the New England Journal of Medicine, an epidemiologist from Boston University School of Medicine (BUSM) believes that further studies are needed. The original study found that on the basis of data from more than 840,000 live births in Denmark, there was no evidence to suggest that the use of the most common...

2010-11-05 10:51:10

(Ivanhoe Newswire) -- The recent approval of a drug may be a cost-effective way to prevent stroke in patients with an irregular heart rhythm. It may also offer patient's better health outcomes than the commonly prescribed and potentially risky blood thinner, warfain. "Dabigatran is the first new drug in 20 years to be approved for stroke prevention in atrial fibrillation, and we wanted to see if it could be cost-effective even before it made its debut in the United States," cardiac...

2010-11-01 16:06:00

RIDGEFIELD, Conn., Nov. 1, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that its new oral anticoagulant, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules, will be available starting Wednesday by prescription in pharmacies across the United States, including CVS/pharmacy, Rite Aid, Walmart, Target, Kmart® and The Kroger Co. In addition, leading independents under the Health Mart®, Good Neighbor...